Bargain in Today's Market (SHOCKING)
This "World's Most Admired" company's stock would be a bargain at $50...Today it's just $2! Plus... a key May 12 announcement could send it ROCKETING skyward...

Click Here Now (Before It's Too Late!)
>>>
Sanjay Shukla, insider at aTyr Pharma

Sanjay Shukla Insider Information

CEO of aTyr Pharma
Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. Dr. Shukla served as our Chief Medical Officer from March 2016 to November 2017. From April 2015 to March 2016, Dr. Shukla worked in an advisory capacity for a number of companies, including as a consultant to aTyr from January 2016 to March 2016. Prior to that, from October 2012 to April 2015, Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, a biopharmaceutical company, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Dr. Shukla served as Chief Executive Officer of RXMD, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates, from April 2009 to September 2012. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma, a biopharmaceutical company, and Aspreva Pharmaceuticals (acquired by Vifor Pharma). Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

What is Sanjay Shukla's net worth?

The estimated net worth of Sanjay Shukla is at least $148,504.72 as of July 1st, 2022. Dr. Shukla owns 40,798 shares of aTyr Pharma stock worth more than $148,505 as of August 15th. This net worth evaluation does not reflect any other assets that Dr. Shukla may own. Additionally, Dr. Shukla receives a salary of $816,410.00 as CEO at aTyr Pharma. Learn More about Sanjay Shukla's net worth.

How old is Sanjay Shukla?

Dr. Shukla is currently 50 years old. There are 4 older executives and no younger executives at aTyr Pharma. Learn More on Sanjay Shukla's age.

What is Sanjay Shukla's salary?

As the CEO of aTyr Pharma, Inc., Dr. Shukla earned a total compensation package of $1,892,708.00 in 2021. Dr. Shukla earned a salary of $510,221.00, options awards of $1,076,297.00, non-equity compensation of $293,377.00, and other compensation of $12,813.00. Learn More on Sanjay Shukla's salary.

How do I contact Sanjay Shukla?

The corporate mailing address for Dr. Shukla and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected] Learn More on Sanjay Shukla's contact information.

Has Sanjay Shukla been buying or selling shares of aTyr Pharma?

Over the course of the past ninety days, Sanjay Shukla has bought $43,200.00 in aTyr Pharma stock. Most recently, on Friday, July 1st, Sanjay Shukla bought 15,000 shares of aTyr Pharma stock. The stock was acquired at an average cost of $2.88 per share, with a total value of $43,200.00. Following the completion of the transaction, the chief executive officer now directly owns 40,798 shares of the company's stock, valued at $117,498.24. Learn More on Sanjay Shukla's trading history.

Who are aTyr Pharma's active insiders?

aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.

Are insiders buying or selling shares of aTyr Pharma?

In the last twelve months, aTyr Pharma insiders bought shares 4 times. They purchased a total of 269,423 shares worth more than $2,077,605.25. The most recent insider tranaction occured on July, 1st when CEO Sanjay Shukla bought 15,000 shares worth more than $43,200.00. Insiders at aTyr Pharma own 4.4 % of the company. Learn More about insider trades at aTyr Pharma.

Information on this page was last updated on 7/1/2022.

Sanjay Shukla Insider Trading History at aTyr Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2022Buy15,000$2.88$43,200.0040,798View SEC Filing Icon  
11/15/2021Buy2,500$8.57$21,425.00View SEC Filing Icon  
5/18/2021Buy10,000$4.01$40,100.0018,298View SEC Filing Icon  
2/9/2021Sell778$7.66$5,959.489,076View SEC Filing Icon  
6/19/2020Buy6,000$4.27$25,620.007,291View SEC Filing Icon  
See Full Table

Sanjay Shukla Buying and Selling Activity at aTyr Pharma

This chart shows Sanjay Shukla's buying and selling at aTyr Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

aTyr Pharma Company Overview

aTyr Pharma logo
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $3.64
Low: $3.40
High: $3.66

50 Day Range

MA: $3.11
Low: $2.63
High: $3.73

2 Week Range

Now: $3.64
Low: $2.60
High: $13.10

Volume

112,774 shs

Average Volume

128,079 shs

Market Capitalization

$102.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!